Margarite sells AMAG 43.73: During the same quarter in the prior year, the firm earned ($0.07) earnings per share.

They set an outperform rating and a $75.00 price objective for the company. Raymond James started coverage on shares of AMAG Pharmaceuticals in a research report on Monday, August 31st. Guggenheim initiated coverage on shares of AMAG Pharmaceuticals in a report on Monday, June 8th. Leerink Swann reissued a buy rating and issued a $85.00 price objective on shares of AMAG Pharmaceuticals in a report on Friday, September 11th. Deutsche Bank reaffirmed a hold rating and set a $75.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, June 25th.


Refugia:
Analysts expect that AMAG Pharmaceuticals will post $5.24 earnings per share for the current fiscal year.

Petronila:
During the same quarter in the prior year, the business posted ($0.07) earnings per share.

Patti:
Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock.

Morgan:
Finally, Raymond James assumed coverage on AMAG Pharmaceuticals in a research report on Monday, August 31st.

Myong:
Jefferies Group initiated coverage on AMAG Pharmaceuticals in a research note on Tuesday, August 18th.

Brittni:
Guggenheim initiated coverage on AMAG Pharmaceuticals in a report on Monday, June 8th.

Juliann:
The company traded as high as $46.60 and last traded at $46.41, with a volume of 449,897 shares traded.

Kathaleen:
Equities analysts expect that AMAG Pharmaceuticals will post $5.24 earnings per share for the current fiscal year.

Erika:
During the same quarter last year, the firm posted ($0.07) earnings per share.

Misty:
They issued an outperform rating and a $75.00 price target on the stock.

Amag Pharmaceuticals (NASDAQ:AMAG)
//stockhand.net/us/?q=nasdaq%3Aamag&id=594171